SynthesisBreast cancer research : BCR2026

CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients: a meta-analysis of Kaplan-Meier-reconstructed individual-level data.

Jasmina Veta Darkovski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.